Habr-Gama Angelita, Perez Rodrigo Oliva, Nadalin Wladimir, Nahas Sérgio Carlos, Ribeiro Ulysses, Silva E Sousa Afonso Henrique, Campos Fábio Guilherme, Kiss Desidério Roberto, Gama-Rodrigues Joaquim
Colorectal Surgery Division, Department of Gastroenterology, University of São Paulo-School of Medicine, São Paulo, Brazil.
J Gastrointest Surg. 2005 Jan;9(1):90-9; discussion 99-101. doi: 10.1016/j.gassur.2004.10.010.
Neoadjuvant chemoradiation treatment (CRT) has resulted in significant tumor downstaging and improved local disease control for distal rectal cancer. The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage. Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy. Patients with incomplete clinical response 8 weeks after CRT completion were treated by radical surgical resection. Patients with complete clinical response were managed by observation alone. Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage. Seventy-one patients (28%) showed complete clinical response (clinical stage 0). One hundred sixty-nine patients showed incomplete clinical response and were treated with surgery. In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease. Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0. Disease-free survival rate showed better results in stage c0, but the results were not significant. Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively. Cancer-related overall and disease-free survival may be correlated to final pathologic staging following neoadjuvant CRT for distal rectal cancer. Also, stage 0 is significantly associated with improved outcome.
新辅助放化疗(CRT)已使低位直肠癌患者肿瘤显著降期,并改善了局部疾病控制情况。本研究的目的是确定这些患者最终分期与生存之间的相关性,而不考虑初始疾病分期。260例被认为可切除的低位(距肛缘0 - 7 cm)直肠腺癌患者接受了新辅助CRT治疗,使用5-氟尿嘧啶和亚叶酸钙加5040 cGy。CRT完成8周后临床反应不完全的患者接受根治性手术切除。临床反应完全的患者仅进行观察。根据Kaplan-Meier曲线和对数秩检验,按照最终分期比较总生存期和无病生存期。71例患者(28%)显示临床反应完全(临床分期0期)。169例患者临床反应不完全,接受了手术治疗。其中22例患者(9%)病理检查显示为pT0 N0 M0(p0期),59例患者(22%)为I期,68例患者(26%)为II期,40例患者(15%)为III期疾病。与p0期相比,c0期的总生存率显著更高(P = 0.01)。无病生存率在c0期显示出更好的结果,但差异不显著。五年总生存率和无病生存率分别为:97.7%和84%(0期);94%和74%(I期);83%和50%(II期);56%和28%(III期)分别。新辅助CRT治疗低位直肠癌后,癌症相关的总生存期和无病生存期可能与最终病理分期相关。此外,0期与改善的预后显著相关。